Piramal Pharma Ltd. delivered strong financial results for the first quarter of FY27, with revenue from operations rising 17.4% year-on-year to ₹2,270 crore, up from ₹1,934 crore in the corresponding period last year. The company reported a narrower consolidated net loss of ₹69.4 crore for the quarter ended June 30, compared with a loss of ₹81.7 crore in the same period last year. According to the company's quarterly earnings filing, the improvement was driven by double-digit growth in CDMO and hospital generics businesses, with operating profitability showing sharp improvement despite the quarterly loss.
Piramal Pharma Ltd has temporarily suspended operations at its manufacturing facilities located in Ahmedabad, Gujarat, due to exceptionally heavy rainfall and flooding in the region. The company suspended operations at its facilities located at Plot Nos. 18 and 19, PHARMEZ Pharmaceutical Special Economic Zone, Village Matoda, Sarkhej Bawla, Ahmedabad, as a precautionary measure following waterlogging. The company has initiated steps to assess the condition of the facilities and facilitate a safe and orderly resumption of operations, with subject to improvement in weather conditions, operations expected to gradually normalise over the next few days. The disclosure was made on July 24, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with Company Secretary & Compliance Officer Maneesh Sharma signing the filing submitted to both BSE Limited and the National Stock Exchange of India Limited.
The affected facilities together account for less than 3% of the company's consolidated revenue, as reported by CNBC TV18. Piramal Pharma added that the assets at the affected facilities are adequately covered under the company's insurance policies. The company stated it will provide further updates, including any material developments or financial implications, as appropriate. All employees, including contract staff, at the affected facilities are safe, according to the company's statement. The confinement of the disruption to facilities accounting for less than 3% of consolidated revenues indicates a diversified operational footprint, with this low concentration risk suggesting that the temporary suspension will not materially alter the company's overall revenue trajectory.
In April this year, Piramal Pharma expects growth to pick up in the financial year 2026-27 (FY27) after a transitional 2025-26 (FY26), with momentum supported by improving demand in its contract development and manufacturing (CDMO) business and new product additions, Chairperson Nandini Piramal said. As reported by CNBC TV18, she said FY26 was impacted by external factors, including macro volatility and product destocking. Piramal guided growth in the coming year, stating "We are guiding for growth around early to mid-teens… and EBITDA to possibly outpace revenue growth."
Shares of Piramal Pharma Ltd ended at ₹181.65, up by ₹0.80, or 0.44%, on the BSE, according to CNBC TV18. The CDMO segment is seeing improved activity, with US biotech funding rising sharply in the second half of FY26, leading to higher order visibility. The company said commercial product growth remained strong, even excluding the impact of a single large product. Despite the operational halt, the company noted that assets at the affected facilities are adequately covered under its insurance policies, with this coverage aiming to mitigate potential losses related to asset damage or business interruption.
